scholarly journals Overexpression of MMP21 and MMP28 is associated with gastric cancer progression and poor prognosis

2018 ◽  
Author(s):  
Jizhen Zhang ◽  
Qi Pan ◽  
Wenhui Yan ◽  
Yiru Wang ◽  
Xujun He ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Progression ◽  
Poor Prognosis ◽  
Gastric Cancer Progression

scholarly journals FERMT1 promotes gastric cancer progression by activating the NF-κB pathway and predicts poor prognosis

2020 ◽  
Vol 21 (9) ◽  
pp. 815-825
Author(s):  
Hua Fan ◽  
Shengjun Zhang ◽  
Yu Zhang ◽  
Wu liang ◽  
Bo Cao
Keyword(s):  
Gastric Cancer ◽  
Cancer Progression ◽  
Poor Prognosis ◽  
Gastric Cancer Progression

scholarly journals Low Expression of FBXO45 Is Associated with Gastric Cancer Progression and Poor Prognosis

2017 ◽  
Vol 37 (1) ◽  
pp. 191-196 ◽  
Author(s):  
NORIMICHI KOGURE ◽  
TAKEHIKO YOKOBORI ◽  
KYOICHI OGATA ◽  
BOLAG ALTAN ◽  
ERITO MOCHIKI ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Progression ◽  
Poor Prognosis ◽  
Gastric Cancer Progression ◽  
Low Expression

scholarly journals SSH1 expression is associated with gastric cancer progression and predicts a poor prognosis

2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Yusufu Maimaiti ◽  
Maimaitiaili Maimaitiming ◽  
Yiliang Li ◽  
Saifuding Aibibula ◽  
Azatijiang Ainiwaer ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Progression ◽  
Poor Prognosis ◽  
Gastric Cancer Progression

MAGE-A family is involved in gastric cancer progression and indicates poor prognosis of gastric cancer patients

2017 ◽  
Vol 213 (8) ◽  
pp. 943-948 ◽  
Author(s):  
Yishui Lian ◽  
Meixiang Sang ◽  
Lina Gu ◽  
Fei Liu ◽  
Danjing Yin ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Cancer Progression ◽  
Poor Prognosis ◽  
Gastric Cancer Patients ◽  
Gastric Cancer Progression

scholarly journals MiR-1284 suppresses gastric cancer progression by targeting EIF4A1

2019 ◽  
Vol Volume 12 ◽  
pp. 3965-3976 ◽  
Author(s):  
Weiyuan Wei ◽  
Wenlong Cao ◽  
Zexu Zhan ◽  
Linhai Yan ◽  
Yubo Xie ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Progression ◽  
Gastric Cancer Progression

scholarly journals Clinical and prognostic significances of cancer stem cell markers in gastric cancer patients: a systematic review and meta-analysis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Mahdieh Razmi ◽  
Roya Ghods ◽  
Somayeh Vafaei ◽  
Maryam Sahlolbei ◽  
Leili Saeednejad Zanjani ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Clinical Outcomes ◽  
Cancer Progression ◽  
Poor Prognosis ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Stem Cell Markers ◽  
Free Survival

Abstract Background Gastric cancer (GC) is considered one of the most lethal malignancies worldwide, which is accompanied by a poor prognosis. Although reports regarding the importance of cancer stem cell (CSC) markers in gastric cancer progression have rapidly developed over the last few decades, their clinicopathological and prognostic values in gastric cancer still remain inconclusive. Therefore, the current meta-analysis aimed to quantitatively re-evaluate the association of CSC markers expression, overall and individually, with GC patients’ clinical and survival outcomes. Methods Literature databases including PubMed, Scopus, ISI Web of Science, and Embase were searched to identify the eligible articles. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were recorded or calculated to determine the relationships between CSC markers expression positivity and overall survival (OS), disease-free survival (DFS)/relapse-free survival (RFS), disease-specific survival (DSS)/ cancer-specific survival (CSS), and clinicopathological features. Results We initially retrieved 4,425 articles, of which a total of 66 articles with 89 studies were considered as eligible for this meta-analysis, comprising of 11,274 GC patients. Overall data analyses indicated that the overexpression of CSC markers is associated with TNM stage (OR = 2.19, 95% CI 1.84–2.61, P = 0.013), lymph node metastasis (OR = 1.76, 95% CI 1.54–2.02, P < 0.001), worse OS (HR = 1.65, 95% CI 1.54–1.77, P < 0.001), poor CSS/DSS (HR = 1.69, 95% CI 1.33–2.15, P < 0.001), and unfavorable DFS/RFS (HR = 2.35, 95% CI 1.90–2.89, P < 0.001) in GC patients. However, CSC markers expression was found to be slightly linked to tumor differentiation (OR = 1.25, 95% CI 1.01–1.55, P = 0.035). Sub-analysis demonstrated a significant positive relationship between most of the individual markers, specially Gli-1, Oct-4, CD44, CD44V6, and CD133, and clinical outcomes as well as the reduced survival, whereas overexpression of Lgr-5, Nanog, and sonic hedgehog (Shh) was not found to be related to the majority of clinical outcomes in GC patients. Conclusion The expression of CSC markers is mostly associated with worse outcomes in patients with GC, both overall and individual. The detection of a combined panel of CSC markers might be appropriate as a prognostic stratification marker to predict tumor aggressiveness and poor prognosis in patients with GC, which probably results in identifying novel potential targets for therapeutic approaches.

Sign in / Sign up

Export Citation Format

Share Document